S&P 500   4,147.19 (+0.05%)
DOW   32,844.24 (+0.12%)
QQQ   321.33 (-0.13%)
AAPL   165.01 (-0.21%)
MSFT   281.18 (-0.61%)
META   172.13 (+3.00%)
GOOGL   117.48 (+0.01%)
AMZN   139.48 (-0.94%)
TSLA   891.66 (+3.14%)
NVDA   174.80 (-7.95%)
NIO   20.31 (+0.45%)
BABA   90.72 (-1.99%)
AMD   99.84 (-2.41%)
MU   61.46 (-1.60%)
T   18.09 (-1.42%)
CGC   3.11 (+15.19%)
GE   75.24 (+1.18%)
F   15.75 (+2.94%)
DIS   109.39 (+2.59%)
AMC   25.37 (+14.38%)
PYPL   96.67 (+1.42%)
PFE   49.08 (-0.39%)
NFLX   236.42 (+4.25%)
S&P 500   4,147.19 (+0.05%)
DOW   32,844.24 (+0.12%)
QQQ   321.33 (-0.13%)
AAPL   165.01 (-0.21%)
MSFT   281.18 (-0.61%)
META   172.13 (+3.00%)
GOOGL   117.48 (+0.01%)
AMZN   139.48 (-0.94%)
TSLA   891.66 (+3.14%)
NVDA   174.80 (-7.95%)
NIO   20.31 (+0.45%)
BABA   90.72 (-1.99%)
AMD   99.84 (-2.41%)
MU   61.46 (-1.60%)
T   18.09 (-1.42%)
CGC   3.11 (+15.19%)
GE   75.24 (+1.18%)
F   15.75 (+2.94%)
DIS   109.39 (+2.59%)
AMC   25.37 (+14.38%)
PYPL   96.67 (+1.42%)
PFE   49.08 (-0.39%)
NFLX   236.42 (+4.25%)
S&P 500   4,147.19 (+0.05%)
DOW   32,844.24 (+0.12%)
QQQ   321.33 (-0.13%)
AAPL   165.01 (-0.21%)
MSFT   281.18 (-0.61%)
META   172.13 (+3.00%)
GOOGL   117.48 (+0.01%)
AMZN   139.48 (-0.94%)
TSLA   891.66 (+3.14%)
NVDA   174.80 (-7.95%)
NIO   20.31 (+0.45%)
BABA   90.72 (-1.99%)
AMD   99.84 (-2.41%)
MU   61.46 (-1.60%)
T   18.09 (-1.42%)
CGC   3.11 (+15.19%)
GE   75.24 (+1.18%)
F   15.75 (+2.94%)
DIS   109.39 (+2.59%)
AMC   25.37 (+14.38%)
PYPL   96.67 (+1.42%)
PFE   49.08 (-0.39%)
NFLX   236.42 (+4.25%)
S&P 500   4,147.19 (+0.05%)
DOW   32,844.24 (+0.12%)
QQQ   321.33 (-0.13%)
AAPL   165.01 (-0.21%)
MSFT   281.18 (-0.61%)
META   172.13 (+3.00%)
GOOGL   117.48 (+0.01%)
AMZN   139.48 (-0.94%)
TSLA   891.66 (+3.14%)
NVDA   174.80 (-7.95%)
NIO   20.31 (+0.45%)
BABA   90.72 (-1.99%)
AMD   99.84 (-2.41%)
MU   61.46 (-1.60%)
T   18.09 (-1.42%)
CGC   3.11 (+15.19%)
GE   75.24 (+1.18%)
F   15.75 (+2.94%)
DIS   109.39 (+2.59%)
AMC   25.37 (+14.38%)
PYPL   96.67 (+1.42%)
PFE   49.08 (-0.39%)
NFLX   236.42 (+4.25%)
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$624.99
+11.38 (+1.85%)
(As of 08/8/2022 12:53 PM ET)
Add
Compare
Today's Range
$617.77
$633.98
50-Day Range
$548.35
$692.80
52-Week Range
$538.01
$747.42
Volume
26,661 shs
Average Volume
695,719 shs
Market Capitalization
$67.84 billion
P/E Ratio
12.47
Dividend Yield
N/A
Price Target
$697.85

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
10.3% Upside
$697.85 Price Target
Short Interest
Bearish
2.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.19mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$1.29 M Sold Last Quarter
Proj. Earnings Growth
4.91%
From $38.89 to $40.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

203rd out of 1,293 stocks

Pharmaceutical Preparations Industry

79th out of 619 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Evercore ISI set a $635.00 price target on Regeneron Pharmaceuticals in a research note on Monday, June 20th. Barclays increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 12th. Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $635.00 to $645.00 and gave the company a "market perform" rating in a report on Wednesday, July 20th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, July 26th. Finally, Jefferies Financial Group cut shares of Regeneron Pharmaceuticals to a "sell" rating and set a $536.00 target price for the company. in a research note on Friday, June 17th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $697.85.

Regeneron Pharmaceuticals Trading Up 2.7 %

Regeneron Pharmaceuticals stock traded up $16.68 during mid-day trading on Monday, hitting $630.29. 23,120 shares of the company's stock were exchanged, compared to its average volume of 695,719. The company's 50 day simple moving average is $598.47 and its 200-day simple moving average is $636.26. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $68.41 billion, a P/E ratio of 12.25, a PEG ratio of 1.97 and a beta of 0.29. Regeneron Pharmaceuticals has a fifty-two week low of $538.01 and a fifty-two week high of $747.42.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.94 by ($0.17). The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The firm's revenue was down 44.4% compared to the same quarter last year. During the same quarter last year, the company earned $27.97 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 38.89 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,100 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $581.53, for a total transaction of $639,683.00. Following the sale, the executive vice president now directly owns 19,644 shares in the company, valued at $11,423,575.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.99% of the stock is owned by insiders.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Regeneron's 'Regeneration' May Not Last Long
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2022
Today
8/08/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$697.85
High Stock Price Forecast
$844.00
Low Stock Price Forecast
$536.00
Forecasted Upside/Downside
+11.7%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.59%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$82.34 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
98,781,000
Market Cap
$67.84 billion
Optionable
Optionable
Beta
0.29

Social Links















REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" REGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in REGN, but not buy additional shares or sell existing shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2022?

19 analysts have issued 1-year price targets for Regeneron Pharmaceuticals' shares. Their REGN stock forecasts range from $536.00 to $844.00. On average, they predict the company's stock price to reach $697.85 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How has Regeneron Pharmaceuticals' stock price performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 at the start of the year. Since then, REGN shares have decreased by 0.5% and is now trading at $628.06.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $9.94 by $0.17. The biopharmaceutical company earned $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.97% and a trailing twelve-month return on equity of 36.17%. The company's revenue for the quarter was down 44.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $27.97 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Loomis Sayles & Co. L P (1.63%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Candriam S.C.A. (0.34%), Handelsbanken Fonder AB (0.18%), DekaBank Deutsche Girozentrale (0.16%) and Mcdonald Capital Investors Inc. CA (0.15%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry, Robert E Landry and Sanofi.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $628.06.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $68.17 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $50.10 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.